155 related articles for article (PubMed ID: 22775493)
21. Impact of Regulatory Incentive Programs on the Future of Pediatric Drug Development.
Yen E; Davis JM; Milne CP
Ther Innov Regul Sci; 2019 Sep; 53(5):609-614. PubMed ID: 30983385
[TBL] [Abstract][Full Text] [Related]
22. Stimulation programs for pediatric drug research--do children really benefit?
Boots I; Sukhai RN; Klein RH; Holl RA; Wit JM; Cohen AF; Burggraaf J
Eur J Pediatr; 2007 Aug; 166(8):849-55. PubMed ID: 17225950
[TBL] [Abstract][Full Text] [Related]
23. Patent extension policy for paediatric indications: an evaluation of the impact within three drug classes in a state Medicaid programme.
Nelson RE; McAdam-Marx C; Evans ML; Ward R; Campbell B; Brixner D; Lafleur J
Appl Health Econ Health Policy; 2011 May; 9(3):171-81. PubMed ID: 21506623
[TBL] [Abstract][Full Text] [Related]
24. An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences.
Kesselheim AS
Milbank Q; 2011 Sep; 89(3):450-502. PubMed ID: 21933276
[TBL] [Abstract][Full Text] [Related]
25. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
26. Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers.
Kesselheim AS; Rome BN; Sarpatwari A; Avorn J
Health Aff (Millwood); 2017 Feb; 36(2):362-370. PubMed ID: 28100464
[TBL] [Abstract][Full Text] [Related]
27. Pharmaceuticals and medical devices: business practices.
; Steiner DJ
Issue Brief Health Policy Track Serv; 2014 Dec; ():1-38. PubMed ID: 25771555
[No Abstract] [Full Text] [Related]
28. The federal preemption debate in pharmaceutical labeling product liability actions.
Gross JM; Curry JA
Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
[No Abstract] [Full Text] [Related]
29. A Method for Approximating Future Entry of Generic Drugs.
Beall RF; Darrow JJ; Kesselheim AS
Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
[TBL] [Abstract][Full Text] [Related]
30. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
Thomson Reuters/West
Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
[No Abstract] [Full Text] [Related]
31. Pediatric Medicine Development: An Overview and Comparison of Regulatory Processes in the European Union and United States.
Penkov D; Tomasi P; Eichler I; Murphy D; Yao LP; Temeck J
Ther Innov Regul Sci; 2017 May; 51(3):360-371. PubMed ID: 28674673
[TBL] [Abstract][Full Text] [Related]
32. Tort claims and federal regulation of medical devices vs pharmaceuticals.
Green M
JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
[No Abstract] [Full Text] [Related]
33. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
Gostin LO
JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
[No Abstract] [Full Text] [Related]
34. Pharmaceuticals and medical devices: business practices.
Steiner DJ
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
[No Abstract] [Full Text] [Related]
35. The case for preemption of prescription drug failure-to-warn claims.
Kim CH
Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
[No Abstract] [Full Text] [Related]
36. To inform or persuade? Direct-to-consumer advertising of prescription drugs.
Berndt ER
N Engl J Med; 2005 Jan; 352(4):325-8. PubMed ID: 15673797
[No Abstract] [Full Text] [Related]
37. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
Kelly C
Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
[TBL] [Abstract][Full Text] [Related]
38. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
39. Teva v. Eisai: what's the real "controversy"?
Wang GL
Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
[TBL] [Abstract][Full Text] [Related]
40. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies.
Roberts R; Rodriguez W; Murphy D; Crescenzi T
JAMA; 2003 Aug; 290(7):905-11. PubMed ID: 12928467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
